Isabelle Rivière, PhD

Director

Share
Print
Share
Print
Pictured: Isabelle Rivière

Office Phone

212-639-7600

Office Fax

917-432-2340

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Isabelle Rivière discloses the following relationships and financial interests:

  • Akron Biotechnology, LLC
    Provision of Services
  • Centre for Commercialization of Cancer Immunotherapy
    Provision of Services
  • Fate Therapeutics
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
  • FloDesign Sonics
    Ownership / Equity Interests; Provision of Services
  • Juno Therapeutics
    Intellectual Property Rights
  • Mnemo Therapeutics
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services (uncompensated)
  • The Georgia Tech Research Corporation (GTRC)
    Provision of Services (uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures